Page 14 - Journal of Structural Heart Disease Volume 3, Issue 5

Original Scienti c Article
140
help explain the low recurrence rate of stroke after an initial cryptogenic stroke.
Con ict of Interest
The authors have no con ict of interest relevant to this publication.
Comment on this Article or Ask a Question
References
1. Pezzini A, Del Zotto E, Magoni M, Costa A, Archetti S, Grassi M, et al. Inherited throm- bophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke. 2003;34:28-33. PMID: 12511746
2. Florez JC, Ay H, Van Cott EM, Buonanno FS. Patent foramen ovale and hypercoagula- bility as combined risk factors for stroke. J Stroke Cerebrovasc Dis. 2003;12:114-118. DOI: 10.1016/S1052-3057(03)00041-7
3. Chaturvedi S. Coagulation abnormal- ities in adults with cryptogenic stroke and patent foramen ovale. J Neurol Sci. 1998;160:158-160. PMID: 9849798
4. Croft AP, Khan JN, Chittari MV, Varma C. Par- adoxical coronary artery embolism caus- ing acute myocardial infarction in a young woman with factor V Leiden thrombophil- lia. J R Coll Physicians Edinb. 2012;42:218- 220. DOI: 10.4997/JRCPE.2012.306
5. Saver JL. Emerging risk factors for stroke: patent foramen ovale, proximal aortic ath- erosclerosis, antiphospholipid antibodies, and activated protein C resistance. J Stroke Cerebrovasc Dis. 1997;6:167-172. PMID: 17894989
6. Tang L, Fang ZF, Zhou SH. Paradoxical embolism causing acute embolic events in a patient with hereditary thrombophil- ia. Herz. 2015;40:314-317. DOI: 10.1007/ s00059-013-3994-9
7. Giardini A, Donti A, Formigari R, Bronzetti G, Prandstraller D, Bonvicini M, et al. Com- parison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. Am J Cardiol. 2004;94:1012- 1016. DOI: 10.1016/j.amjcard.2004.06.056
8. Bushnell CD, Goldstein LB. Diagnostic test- ing for coagulopathies in patients with ischemic stroke. Stroke. 2000;31:3067- 3078. PMID: 11108774
9. Dodge SM, Hassell K, Anderson CA, Keller J, Groves B, Carroll JD. Antiphospholipid antibodies are common in patients re- ferred for percutaneous patent foramen ovale closure. Catheter Cardiovasc Interv. 2004;61:123-127. DOI: 10.1002/ccd.10754
10. Tomomasa R, Yamashiro K, Tanaka R, Hat- tori N. Cerebral infarction in an HIV-in- fected patient with combined protein S and C de ciency and a patent fora- men ovale. J Stroke Cerebrovasc Dis. 2013;22:e650-e652. DOI: 10.1016/j.jstroke- cerebrovasdis.2013.04.019
11. Rajamani K, Chaturvedi S, Jin Z, Homma S, Brey RL, Tilley BC, et al. Patent foramen ovale, cardiac valve thickening, and an- tiphospholipid antibodies as risk factors for subsequent vascular events: the PICSS- APASS study. Stroke. 2009;40:2337-2342. DOI: 10.1161/STROKEAHA.108.539171
12. Rosendaal FR, Helmerhorst FM, Van- denbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22:201-210. PMID: 11834517
13. Greep NC, Liebeskind DS, Gevorgyan R, Truong T, Cua B, Tseng CH, et al. Associ- ation of ischemic stroke, hormone ther- apy, and right to left shunt in postmeno- pausal women. Catheter Cardiovasc Interv. 2014;84:479-485. DOI: 10.1002/ccd.25431
14. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092-1100. DOI: 10.1056/ NEJMoa1301440
Journal of Structural Heart Disease, October 2017
Volume 3, Issue 5:135-140
Cite this article as: Kar S, Noureddin N, Aboulhosn J, Mahmzi Y, Coluzzi A, Tobis JM. Percutaneous Closure of Patent Foramen Ovale or Atrial Septal Defect in the Presence of Thrombophilia. Structural Heart Disease. 2017;3(5):135-140. DOI: https://doi. org/10.12945/j.jshd.2017.018.17